![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
GW Pharm. | LSE:GWP | London | Ordinary Share | GB0030544687 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 735.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMGWP RNS Number : 8094Y GW Pharmaceuticals PLC 10 September 2009 GW Pharmaceuticals to present at Rodman & Renshaw Annual Global Investment Conference Porton Down, UK, 10 September 2009: GW Pharmaceuticals plc (AIM: GWP) announces that its Managing Director, Justin Gover, will be presenting at the Rodman & Renshaw Annual Global Investment Conference in New York on Thursday, September 10, 2009 at 3.40 pm EDT (8.40 pm BST). Investors may access a live webcast of the presentation at www.gwpharm.com on the presentations page under the Investor Relations tab. An archived version of the presentation will be available later that day. Enquiries: +-------------------------------------+------------------------------------+ | GW Pharmaceuticals plc | Today: +44 20 7831 3113 | +-------------------------------------+------------------------------------+ | Justin Gover, Managing Director | Thereafter: + 44 1980 557000 | +-------------------------------------+------------------------------------+ | | | +-------------------------------------+------------------------------------+ | Financial Dynamics | Tel: +44 20 7831 3113 | +-------------------------------------+------------------------------------+ | Ben Atwell, John Dineen | | +-------------------------------------+------------------------------------+ Notes to Editors About GW GW was founded in 1998 and listed on the AIM, a market of the London Stock Exchange, in June 2001. Operating under license from the UK Home Office, the company researches and develops cannabinoid pharmaceutical products for patients who suffer from a range of serious ailments, in particular multiple sclerosis and cancer pain. GW has assembled a large in-house scientific team with expertise in cannabinoid science as well as experience in the development of both plant-based prescription pharmaceutical products and medicines containing controlled substances. GW occupies a world leading position in cannabinoids and has developed an extensive international network of the most prominent scientists in the field. For more information, visit www.gwpharm.com This information is provided by RNS The company news service from the London Stock Exchange END MSCDGGGLVLDGLZM
1 Year Gw Pharmaceuticals Chart |
1 Month Gw Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions